Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Investor Update
Get the latest updates from Investor Update directly as they happen.
Follow now 374 followers
Latest posts
Last updated 4 days ago
Invitation to Roche’s Virtual ADA Investor Event
4 days ago
We are pleased to invite investors and analysts to participate in our...
Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics
4 days ago
PathAI’s best-in-class Image Management System (IMS) with advanced AI analysis and workflow...
Invitation to Roche’s Investor Event at ASCO 2026
11 days ago
The Roche Investor Relations team would like to invite you to an...
Reminder: Invitation to Roche’s Diagnostics Day 2026
13 days ago
The Roche Investor Relations team would like to invite you to the...
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5% in CHF due to the significant appreciation of the Swiss franc
18 days ago
Group sales were +6% at constant exchange rates (CER)1, -5% when reported...
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5% in CHF due to the significant appreciation of the Swiss franc
18 days ago
Group sales were +6% at constant exchange rates (CER)1, -5% when reported...
Roche’s fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS
19 days ago
Late-breaking Phase III FENhance 1 and 2 study results showed superiority of...
Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD
20 days ago
Phase III METEOROID study met its primary endpoint in patients with myelin...
FDA accepts application for Roche’s Gazyva/Gazyvaro for the treatment of the most common form of lupus
20 days ago
Filing acceptance based on phase III ALLEGORY data for Gazyva/Gazyvaro showing a...
Foundation Medicine to Strengthen Monitoring Portfolio with SAGA Diagnostics’ Tumor-Informed Molecular Residual Disease (MRD) Platform
25 days ago
Pathlight™, a personalized, tumor-informed molecular residual disease (MRD) platform, will expand Foundation...
Reminder: Invitation to Roche’s First Quarter Sales 2026 Presentation
25 days ago
Roche will publish its Sales Results for the 1st Quarter 2026 prior...
Reminder: Invitation to Roche’s Virtual AAN Investor Event
26 days ago
We are pleased to invite investors and analysts to participate in our...